Screener
Indivior Pharmaceuticals, Inc. INDV Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 12) | ||
| Stockholders' deficit | ||
| Common stock, par value $0.001 per share (2026) and $0.50 per share (2025). Issued shares: 122 (2026) and 125 (2025) | — | 62 |
| Additional paid-in capital | 165 | 112 |
| Accumulated other comprehensive loss | (29) | (30) |
| Accumulated deficit | (280) | (243) |
| Total stockholders' deficit | (144) | (98) |
| Total liabilities and stockholders' deficit | $1,197 | $1,201 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s total equity?
- Indivior Pharmaceuticals, Inc. (INDV) reported total equity of -$144M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s total equity increased by 49.5% year-over-year, from -$285M to -$144M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s total equity?
- Over 4 years (2021 to 2025), Indivior Pharmaceuticals, Inc.'s total equity has grown at a -5.1% compound annual growth rate (CAGR), from $121M to -$98M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Indivior Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude